Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Biogen's Fampyra Gains Conditional Approval In Europe

This article was originally published in The Pink Sheet Daily

Executive Summary

Biogen must prove additional drug benefits in further study to gain full approval.

You may also be interested in...



CHMP Positive On Trajenta, Vectibix, Votubia And Eurartesim, But Negative On Bronchitol, Luveniq And Glybera

Europe's scientific advisory panel recommends Boehringer Ingelheim's Trajenta and Novartis's Votubia for approval, and clears new indications for Amgen's Vectibix.

Amid A Flurry Of EU Positive Opinions Benlysta And Yervoy Shine, While Fampyra Is Reborn

The European Medicines Agency has recommended an impressive number of drugs for approval, including Merck & Co's hepatitis C therapy, Victrelis, Theravance's Vibativ and Amgen's Xgeva.

GSK's Votrient Gains Conditional EU Approval For Renal Cell Carcinoma

Regulators still want to see how GlaxoSmithKline's pazopanib compares with Pfizer's sunitinib

Related Content

Topics

UsernamePublicRestriction

Register

PS078529

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel